Measles-mumps-rubella vaccine at 6  months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial
AbstractBackgroundMeasles is a highly contagious and serious infection. Before the introduction of vaccination, measles caused yearly epidemics putting vulnerable children at risk of brain damage and death. Despite safe and cost-effective vaccines, measles remains a leading cause of death in children globally. Due to insufficient vaccine coverage and low levels of in utero transferred antibodies from vaccinated mothers, outbreaks of measles in Denmark and other high-income countries are observed at increasing frequency.The current vaccine was introduced in Denmark in 1987 as a one-shot measles-mumps-rubella vaccine at 15 â...
Source: Trials - December 10, 2020 Category: Research Source Type: clinical trials
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11
Condition:  Epidemic Parotitis, Mumps Interventions:  Biological: Attenuated Mumps vaccine (KMB-17) in phase II and III;  Biological: Placebo in phase II;  Biological: Attenuated Mumps vaccine (KMB-17) in phase III;  Biological: Placebo in phase III Sponsors:  Chinese Academy of Medical Sciences;  Hubei Provincial Center for Disease Control and Prevention Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials
